Author Archives: Punit Dhillon
I had the great privilege of speaking with Cheddar about the importance of cancer immunotherapy and OncoSec’s role in the fight to end cancer. We discuss the advantages of intratumoral therapy, the future of cancer care, and how OncoSec is positioned to solve a great unmet need in oncology. Check out the full interview for more!
In President Donald Trump’s address to joint sessions of Congress, he announced the White House is planning to unveil a new executive order on immigration tailored to respond to recent court rulings. As you may know, federal judges put a hold on the President’s original executive order banning travelers from seven majority-Muslim countries to enter the US. Continue reading →
Continue reading →
In December, the healthcare industry rejoiced as the 21st Century Cures Act achieved overwhelming bipartisan support in Congress and was signed into law by Former President Obama. The new legislation aims to increase funding for cancer research, speed the development and approval of new treatments, and strengthen mental health services. Continue reading →
Continue reading →
There are thousands of do-it-yourself seminars, books, and articles to help entrepreneurs achieve success. Business leaders continually look for the latest advancements and insights into what can make their company great. But sometimes the answer can be right underneath your nose, and it’s one of the most inherent, yet commonly overlooked aspects of a company.
It’s no mystery that millennials are changing the workforce and quickly rising up the ranks. By 2030, millennials will be approximately 75 per cent of the global workforce. Based on numbers alone, Millennials are accelerating change and growth in the office.
Immunotherapy is changing the way we perceive and treat cancer. Advances in science and technology have brought about a new wave of promising cancer immunotherapies, which harness the immune system to fight disease. Melinda Welsh documented her diagnosis and treatment of squamous cell carcinoma of the head and neck with ImmunoPulse IL-12 in the Los Angeles Times.
At OncoSec, we are committed to providing timely corporate updates, including recent achievements and upcoming milestones. We are pleased to provide brief recaps of our conference calls to further expand our avenues of communication. We hope these continued activities enhance shareholder engagement, and I look forward to sharing more updates with you.